Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial
J. Smith (Manchester, United Kingdom), E. Ballantyne (Stevenage, United Kingdom), M. Kerr (Stevenage, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Morice (Cottingham, United Kingdom), M. Sher (Largo, Florida, United States of America), M. Trower (Stevenage, United Kingdom), S. Pawsey (Stevenage, United Kingdom)
Source: International Congress 2019 – Highlights in lung function and chronic cough
Session: Highlights in lung function and chronic cough
Session type: Poster Discussion
Number: 600
Disease area: Airway diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Smith (Manchester, United Kingdom), E. Ballantyne (Stevenage, United Kingdom), M. Kerr (Stevenage, United Kingdom), L. Mcgarvey (Belfast, United Kingdom), A. Morice (Cottingham, United Kingdom), M. Sher (Largo, Florida, United States of America), M. Trower (Stevenage, United Kingdom), S. Pawsey (Stevenage, United Kingdom). Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial. 600
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: